# Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

> **NCT01410500** · — · APPROVED_FOR_MARKETING · sponsor: **Amgen**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT01410500
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01410500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01410500, "Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01410500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*